目的：观察Tju103和CTLA4-Ig各自对MHC半相合小鼠骨髓移植免疫耐受的诱导。方法：半相合供鼠T细胞与受鼠抗原、Tju103(或CTLA4-Ig）共育后与骨髓细胞混合移植，观测移植后受情况。结果：A. 单纯照射组：全部小鼠于照射后11 d内死于造血衰竭； B. 白血病CTX治疗组：全部小鼠于接种白血病细胞后16～23 d死于白血病； C. 单纯移植组：全部小鼠于移植后21 d内死于移植物抗宿主病（GVHD）； D. CsA预防组：5只小鼠于移植后8～22 d死亡， 1只死于白血病，各有2只死于GVHD和感染，5只活过30 d； E. Tju103处理组：4只小鼠于移植后9～26 d死亡，2只死于GVHD，各有1只死于白血病和感染，6只活过30 d； F. CTLA4-Ig 处理组：2只小鼠于移植后17～26 d死亡GVHD，8只活过30 d。结论：Tju103和CTLA4-Ig均明显延长生存期，降低GVHD发生和严重程度，CTLA4-Ig保留有抗感染和移植抗白血病（GVL）作用，而Tju103没有。

Objective:To observe the respective effects of Tju103 and CTLA4-Ig on tolerance, post haploidentical mice bone marrow transplantation. Methods:In the presence of the recipient antigen, T cells from the haploidentical donors were first cultured with Tju103 or CTLA4-Ig, then mixed with the bone marrow cells and transfused into the recipients. At last, they were observed on the effect on tolerance post transplantation. Results: A. The only irradiated group: All the mice died of failure of hematopoiesis within 11 days post irradiation. B. The CTX-treated leukemia group: All the mice died of leukemia within 16-23 days. C.The only transplanted group: All cases died of GVHD within 21 days post transplantation. D. The CsA prophylaxis group: 5 mice died within 8-22 days after transplantation, of which one died of leukemia, and two died of GVHD and infection respectively leaving 5 survived over 30 days post transplantation. E. The Tju103 treated group: 4 mice died within 9-26 days post transplantation, of which one died of leukemia and infection respectively, and two died of GVHD leaving 6 mice survived over 30 days post transplantation. F. The CTLA4-Ig treated group: 2 mice died of GVHD within 17~26 days after transplantation leaving 8 survived over 30 days post transplantation. Conclusions:Tju103 or CTLA4-Ig could alone improve survival time and reduce incidence and degree of GVHD respectively. But CTLA4-Ig could preserve ability of GVL effect and anti-infection potential while Tju103 couldn′t.

军队医学科学基金十五重点课题项目（01Z050）